Quantcast

Latest AstraZeneca Stories

2014-06-12 16:26:24

SAN FRANCISCO, June 12, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIK(TM )(naloxegol oxalate), an investigational...

2014-06-12 08:29:42

DUBLIN, June 12, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/l2jzql/antibacterial) has announced the addition of the "Antibacterial Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 This report on antibacterial drugs market studies the current as well as future prospects of the market globally. The market for antibacterial drugs...

2014-06-11 16:24:35

RnRMarketResearch.com adds "Next-Generation Biologics R&D, Industry and Market 2014-2024" on its store. Order a purchase copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=185532 . DALLAS, June 11, 2014 /PRNewswire-iReach/ -- Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical...

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-09 23:06:34

Markets Research Reports.biz added deep and professional market research report on "Global Influenza [Flu] Vaccine Market Trends and Opportunities 2014-19" Market Analysis and Overview. Albany, NY (PRWEB) June 09, 2014 With the advancement in technology and discovery of new products in the field of medical sciences, vaccines have gained a crucial position in the pharmaceutical industry. Vaccines are considered as the most effective health intervention ever developed, saving...

2014-06-04 23:01:36

The just-filed lawsuit was filed by a group of consumers who allege that the maker and distributor of Crestor, prescribed to lower cholesterol levels, allegedly hid information on the drug’s serious, adverse health reactions. Port Washington, NY (PRWEB) June 04, 2014 Parker Waichman LLP, a national law firm that has long been dedicated to protecting the rights of consumers who have suffered injuries due to dangerous drugs comments on a recent lawsuit filed on May 29, 2014 in the United...

2014-06-04 12:28:56

TUCSON, Ariz., June 4, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, today announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only...

2014-06-03 12:39:42

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The Prostate Cancer Therapeutics Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/treatments/prostate_cancer_therapeutics_market_2013_2023.html Report DetailsProstate cancer therapeutics - assess products, developments, and revenue prospectsHow are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023....

2014-06-03 12:37:54

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Asthma and COPD Therapies: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/diseases/asthma/asthma_copd_therapies.html Report DetailsNew study reveals sales potential of this large, expanding marketSee what the future holds for asthma and COPD therapies. Visiongain's report gives you drug revenue predictions to 2023. You find data, trends, opportunities and commercial...

2014-05-30 12:26:02

MERIDEN, Conn., May 30, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza. UMN Pharma, which is partnered with Astellas, holds an exclusive license from Protein Sciences for the development and marketing...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related